search 2013 adfgs

Diagnostics and Personalized Medicine Committee

The BioNJ Diagnostics and Personalized Medicine Committee was created to advance personalized medicine through diagnostics by identifying and supporting partnerships with industry, academic, government and investors in the State of New Jersey.
The goal of the committee is to define and accelerate new areas of diagnostics, such as in vivo and in vitro tests, biomarkers, imaging, information systems and other innovative technologies.

Shiv Krishnan, Ph.D., Senior Director, Scouting & Partnering – US of Sanofi R&D; Elias Zerhouni, M.D., President, Global R&D of Sanofi; Kathleen Otto, Vice President, Business Development of BioNJ; G. Steven Burrill, CEO of Burrill & Company; Marc Bonnefoi, DVM, Ph.D., Head of the North America R&D Hub and Vice President of Disposition, Safety and Animal Research Scientific Core Platform of Sanofi; and Edward Abrahams, Ph.D., President of the Personzalized Medicine Coalition at the 2013 BioNJ Dx & PM Innovation Summit on June 6, 2013 at Sanofi.

G. Steven Burrill, CEO of Burrill & Company; Debbie Hart, President and CEO of BioNJ; Shiv Krishnan, Ph.D., Senior Director, Scouting and Partnering – US of Sanofi R&D; and Roomi Nusrat, M.D., CEO of Aesclepius Sciences LLC at the 2013 BioNJ Dx & PM Innovation Summit on June 6, 2013 at Sanofi.

Past Events

June 6, 2013: Second Annual Diagnostics & Personalized Medicine Innovation Summit
December 13, 2012: Diagnostics & Personalized Medicine Breakfast Briefing
March 14, 2012: Diagnostics and Personalized Medicine Innovation Summit & Funding Roundtable
May 23-24, 2011: BioPartnering Conference: Bringing Together the Biotech, Diagnostics and Big Pharma Communities.
May 5, 2011: Diagnostics and Personalized Medicine Webinar
September 2010: New Jersey Gets Personalized Breakfast Briefing
July 2010: Kickoff Diagnostic Webinar Featuring G. Steven Burrill

Committee Members

Peter Hoehn, Committee Co-Chair, Global Business Leader, Janssen Diagnostics
Pascal Yvon, PharmD, MBA, Committee Co-Chair, President, BioSciences Expansion
Andrew Brooks, Ph.D., Chief Operating Officer, RUCDR, Infinite Biologics
Ger Brophy, B.Sc., Ph.D., General Manager, New Product Development, Medical Diagnostics, GE Healthcare
Shana Fried, Senior Associate, Reed Smith LLP
Guanghui Hu, President, Admera Health
Courtney Kronenthal, Ph.D., Director, Communications & Development, Coriell Institute for Medical Research
Nancy Lurker, Chief Executive Officer, PDI Inc.
Janet McKim, Director of Development, Human Genetics Institute of NJ, RUCDR, Infinite Biologics
Joe Montemarano, MIRTHE Executive Director, Princeton University
Christopher Moxham, Ph.D., Associate Vice President, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Co.
Roomi Nusrat, M.D., Aesclepius Sciences
Lieven Nuyttens, Chief Executive Officer, US Division, FluidDA, Inc.
Kathleen Otto, Vice President, Business Development, BioNJ
Kapila Ratnam, Principal, NewSpring Capital
Panna Sharma, President & Chief Executive Officer, Cancer Genetics, Inc.
Jacqueline Threadgill, Senergene Solutions
Peter Tolias, Ph.D., Director, Center for Healthcare Innovation and Professor, Department of Chemistry, Chemical Biology and Biomedical Engineering, Stevens Institute of Technology

Members of the BioNJ Diagnostics and Personalized Medicine Committee join May 2011 Webinar Panelists at BioNJ Headquarters.


Video Archive

      

If you are interested in becoming a sponsor of the BioNJ Diagnostics and Personalized Medicine Committee, please contact Kathleen Otto at KOtto@BioNJ.org or by phone at 609-890-3185.